Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,847.72 +3,792.10 (+6.42%) CMC Crypto 200
1,352.33 +75.35 (+5.91%)
AMGN May 2024 242.500 put
| Previous close | 0.0900 |
| Open | 0.2400 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 242.50 |
| Expiry date | 2024-05-03 |
| Day's range | 0.0800 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 149 |
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Barrons.comThese Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.
The TelegraphInterest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise
Traders have pulled forward their expectations for the first interest rate cuts in the US as the economy added fewer jobs than expected.
